{"database": "lobbying", "table": "lobbying_activities", "rows": [[1921661, "ac60a372-51fa-4eba-a3d0-7047c3f3f378", "Q4", "FOLEY & LARDNER LLP", 15042, "ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY", 2016, "fourth_quarter", "PHA", "FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market; Issues relating to the Comprehensive Addiction and Recovery Act of 2016.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2017-01-19T11:21:33-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1921661"], "units": {}, "query_ms": 32.802295056171715, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}